These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 30355587)

  • 21. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
    Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
    Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma.
    Mansoor I; Calam RR; Al-Khafaji B
    Anal Quant Cytol Histol; 2008 Feb; 30(1):25-32. PubMed ID: 18459584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study.
    Ribal MJ; Mengual L; Lozano JJ; Ingelmo-Torres M; Palou J; Rodríguez-Faba O; Witjes JA; Van der Heijden AG; Medina R; Conde JM; Marberger M; Schmidbauer J; Fernández PL; Alcaraz A
    Eur J Cancer; 2016 Feb; 54():131-138. PubMed ID: 26761785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
    Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
    Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Xpert bladder cancer monitor in surveillance of bladder cancer: Systematic review and meta-analysis.
    Sharma G; Sharma A; Krishna M; Devana SK; Singh SK
    Urol Oncol; 2022 Apr; 40(4):163.e1-163.e9. PubMed ID: 34535354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
    Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
    Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
    Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
    BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
    Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
    Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
    Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
    Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors.
    Coskuner E; Cevik I; Ozkan A; Dillioglugil O; Akdas A
    Int Urol Nephrol; 2012 Jun; 44(3):793-8. PubMed ID: 22371126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
    Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
    Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck® as a diagnostic tool in upper urinary tract tumor.
    Palermo M; D'Elia C; Trenti E; Comploj E; Mian C; Schwienbacher C; Heidegger I; Clauser S; Pycha A; Vjaters E
    Minerva Urol Nephrol; 2024 Apr; 76(2):195-202. PubMed ID: 38498297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer.
    Mungan NA; Vriesema JL; Thomas CM; Kiemeney LA; Witjes JA
    Urology; 2000 Nov; 56(5):787-92. PubMed ID: 11068302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer.
    Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Aufderklamm S; Böttge J; Rausch S; Mischinger J; Bier S; Gakis G; Kuehs U; Stenzl A; Schwentner C
    Dis Markers; 2014; 2014():973406. PubMed ID: 25587206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.